Late stage? That's like checking after the fact. A bit pointless. Of course, it can be useful if they can develop it further to detect early stage cases. Will take some time thought, as they need like phase 1, 2 and 3 trials, and a large sample. Won't be in the market for another few years, I reckon, unless they get approval to speed it up.
